Showing 1 - 3 results of 3 for search 'Katia Mancuso', query time: 0.01s Refine Results
  1. 1
    Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma

    Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma by Andrea Poletti, Barbara Taurisano, Gaia Mazzocchetti, Marta Lionetti, Marina Martello, Viola Meixian Vuong, Vincenza Solli, Giulia Marzocchi, Akihiro Maeda, Ilaria Vigliotta, Enrica Borsi, Silvia Armuzzi, Ignazia Pistis, Alessio Marella, Sonia Fabris, Paola Tacchetti, Katia Mancuso, Ilaria Rizzello, Lucia Pantani, Nicoletta Testoni, Michele Cavo, Elena Zamagni, Niccolò Bolli, Carolina Terragna

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial

    Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial by Sara Bringhen, Lorenzo Cani, Nicola Giuliani, Silvia Mangiacavalli, Giulia Benevolo, Elisabetta Antonioli, Renato Zambello, Roberto Ria, Iolanda Donatella Vincelli, Sonia Ronconi, Sonia More, Antonietta Pia Falcone, Alessandro Allegra, Mattia D'Agostino, Andrea Evangelista, Andrea Capra, Elisa Sciorsci, Paola Curci, Patrizia Tosi, Anna Marina Liberati, Anna Maria Cafro, Angelo Belotti, Francesca Patriarca, Donato Mannina, Katia Mancuso, Francesco Cattel, Giovannino Ciccone, Benedetto Bruno, Mario Boccadoro, Alessandra Larocca

    Published 2025-07-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients

    Lenalidomide maintenance after bortezomib, thalidomide and dexamethasone (VTD) induction and autologous stem cell transplantation: an Italian real-life study of 602 patients by Gregorio Barilà, Angela Grassi, Concetta Conticello, Roberto Mina, Chiara Marcon, Francesca Fazio, Claudio Salvatore Cartia, Martina Tinelli, Maria Livia Del Giudice, Sofia Pilerci, Angelo Belotti, Anna Pascarella, Mariantonietta Tafuri, Serena Rocchi, Katia Mancuso, Nicola Sgherza, Giuseppe Mele, Edoardo Scomazzon, Massimo Gentile, Marika Porrazzo, Norbert Pescosta, Anna Furlan, Massimiliano Arangio Febbo, Cristina Clissa, Andrea Casson, Rossella Ribolla, Antonio Maroccia, Chiara Lisi, Enrica Antonia Martino, Ombretta Annibali, Gabriele Buda, Elisabetta Antonioli, Silvia Mangiacavalli, Alberto Tosetto, Pellegrino Musto, Francesca Gay, Elena Zamagni, Maria Teresa Petrucci, Francesco Di Raimondo, Francesca Patriarca, Renato Zambello

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: